It was recently shown that pre-conditioning with cyclophosphamide could favorably modify the immunosuppressive TME, yielding durable curative responses of prostate stem cell antigen-targeting 4-1BB-co-stimulated CAR-T cells in metastatic prostate and pancreas cancer models [133]. This evidence concerns the gene PSCA and prostatitis.